⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685416 | 0.78 | NPSR1 (0.35) | — | |
| SCHEMBL3818020 | 0.67 | — | — | |
| SCHEMBL23829741 | 0.65 | — | — | |
| SCHEMBL17112968 | 0.64 | — | — | |
| SCHEMBL3818018 | 0.62 | — | — | |
| SCHEMBL29952835 | 0.61 | — | — | |
| SCHEMBL29512320 | 0.61 | — | — | |
| SCHEMBL30166905 | 0.60 | — | — | |
| SCHEMBL30331543 | 0.60 | — | — | |
| SCHEMBL8338807 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | claimed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | claimed |
| WO-2020255017-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | claimed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| CN-114867717-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-109678859-B | Dihydropyrimidine compound and application thereof in medicine | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3658554-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | North & South Brother Pharmacy Investment Company Limited (CN) | 2020-06-03 | — | — | EP | disclosed |
| CN-109348715-A | pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2019-02-15 | — | — | CN | disclosed |
| WO-2019001396-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-01-03 | — | — | WO | disclosed |
| EP-3122747-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-02-01 | — | — | EP | disclosed |
| CN-102592040-B | The method of drug discovery | 基德姆生物科学有限公司 | 2016-12-21 | — | — | CN | disclosed |
| EP-1540329-A4 | DRUG DISCOVERY METHOD | KEDDEM BIO SCIENCE LTD (IL) | 2009-06-10 | — | — | EP | disclosed |
| US-20050277117-A1 | Drug discovery method | KEDDEM BIO-SCIENCE LTD. (IL) | 2005-12-15 | — | — | US | disclosed |
| CN-1668918-A | Methods of Drug Discovery | KEDDEM BIO SCIENCE LTD (IL) | 2005-09-14 | — | — | CN | disclosed |
| EP-1546113-A1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | Bayer HealthCare AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1540329-A1 | DRUG DISCOVERY METHOD | KEDDEM BIO-SCIENCE LTD. (IL) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024700-A1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | BAYER HEALTHCARE AG (DE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004010136-A1 | DRUG DISCOVERY METHOD | KEDDEM BIO-SCIENCE LTD. (IL) | 2004-01-29 | — | — | WO | disclosed |
| EP-0994859-A1 | COMPOUNDS | Astra Aktiebolag (publ) (SE) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001437-A1 | COMPOUNDS | ASTRA AKTIEBOLAG (PUBL) (SE) | 1999-01-14 | — | — | WO | disclosed |